Materiały źródłowe

• #1 Atypical hyperplasia of the breast | Beacon Health System

  https://www.beaconhealthsystem.org/library/diseases-and-conditions/atypical-hyperplasia-of-the-breast?content_id=CON-20369759

  Atypical hyperplasia of the breast is the development of precancerous cells in the breast. Atypical hyperplasia causes a buildup of cells in the breast tissue. When viewed with a microscope, the cells look different from typical breast cells. […] Atypical hyperplasia of the breast isn’t breast cancer. But it’s a sign that you have an increased risk of breast cancer in the future. […] Atypical hyperplasia of the breast is most often diagnosed during a breast biopsy. A breast biopsy is a procedure to remove a sample of breast tissue for testing. It’s often done if something concerning is found during a clinical breast exam or on an imaging test, such as a mammogram or an ultrasound.

• #2 Atypical hyperplasia of the breast – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/symptoms-causes/syc-20369773

  Atypical hyperplasia of the breast is the development of precancerous cells in the breast. Atypical hyperplasia causes a buildup of cells in the breast tissue. When viewed with a microscope, the cells look different from typical breast cells. […] Atypical hyperplasia of the breast is typically found during a breast biopsy. A breast biopsy is a procedure to remove some breast cells for testing. It’s often recommended if something concerning is found on a mammogram or an ultrasound. A biopsy also might be done to investigate a breast concern, such as a lump. […] Atypical hyperplasia of the breast happens when cells in the breast tissue develop changes in their DNA. A cell’s DNA holds the instructions that tell the cell what to do. The changes tell the cell to make many more cells. This causes a buildup of cells in the breast. Healthcare professionals call this buildup hyperplasia. The changes also turn the cells into atypical cells. This means that the cells look different from typical cells.

• #3 Atypical hyperplasia of the breast | Health Library | Memorial Health System

  https://www.mhsystem.org/health-library/con-20369759/

  Atypical hyperplasia of the breast is most often diagnosed during a breast biopsy. A breast biopsy is a procedure to remove a sample of breast tissue for testing. Its often done if something concerning is found during a clinical breast exam or on an imaging test, such as a mammogram or an ultrasound. […] Atypical hyperplasia of the breast usually doesnt cause any symptoms. […] Atypical hyperplasia of the breast is typically found during a breast biopsy. A breast biopsy is a procedure to remove some breast cells for testing. Its often recommended if something concerning is found on a mammogram or an ultrasound. […] Atypical hyperplasia of the breast is the development of precancerous cells in the breast. Atypical hyperplasia causes a buildup of cells in the breast tissue. When viewed with a microscope, the cells look different from typical breast cells.

• #4 Hyperplasia and atypical hyperplasia | Breast Cancer Now

  https://breastcancernow.org/about-breast-cancer/breast-lumps-and-benign-not-cancer-breast-conditions/hyperplasia-and-atypical-hyperplasia/

  Atypical hyperplasia (also called epithelial hyperplasia) happens when cells lining the ducts or lobules increase in number and develop an unusual pattern or shape. […] Atypical hyperplasia is also benign (not cancer). However, having atypical hyperplasia has been shown to increase the risk of breast cancer in some people. […] Hyperplasia and atypical hyperplasia do not usually cause any symptoms. Because of this, they’re usually found by chance when breast tissue that has been removed during a biopsy or breast surgery is examined under a microscope in the laboratory. […] If you have atypical hyperplasia, your doctor may want you to have more tissue removed to examine the area more thoroughly. […] In both cases, the tissue removed will be sent to a laboratory to be examined under a microscope. This will confirm the diagnosis of atypical hyperplasia and check for any changes that could be breast cancer.

• #5 Atypical hyperplasia of the breast – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/diagnosis-treatment/drc-20369778

  Atypical hyperplasia of the breast is most often diagnosed during a breast biopsy. A breast biopsy is a procedure to remove a sample of breast tissue for testing. It’s often done if something concerning is found during a clinical breast exam or on an imaging test, such as a mammogram or an ultrasound. […] Not everyone with atypical hyperplasia of the breast needs surgery. Some healthcare teams may not recommend surgery if there is a low risk of finding cancer. The level of risk may depend on the findings of your mammogram images and other factors, such as your medical history and past breast operations. Your healthcare team carefully considers your biopsy results and your other health conditions when choosing the treatment plan that’s best for you. […] Atypical hyperplasia of the breast increases the risk of breast cancer. So your healthcare team creates a breast cancer screening plan. You might have more-frequent screening or different screening tests than would someone with an average risk of breast cancer.

• #6 Atypical hyperplasia of the breast // Middlesex Health

  https://middlesexhealth.org/learning-center/diseases-and-conditions/atypical-hyperplasia-of-the-breast

  Atypical hyperplasia of the breast is most often diagnosed during a breast biopsy. A breast biopsy is a procedure to remove a sample of breast tissue for testing. It’s often done if something concerning is found during a clinical breast exam or on an imaging test, such as a mammogram or an ultrasound. […] Treatment for atypical hyperplasia of the breast may involve surgery to remove the atypical cells. Not everyone needs surgery. Your healthcare team might recommend more-frequent breast cancer screening to watch for signs of breast cancer. You also might consider medicine to lower your risk of breast cancer. […] Atypical hyperplasia of the breast increases the risk of breast cancer. So your healthcare team creates a breast cancer screening plan. You might have more-frequent screening or different screening tests than would someone with an average risk of breast cancer.

• #7 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Biopsy samples taken from your breast are studied by a doctor with special training, called a pathologist. After testing the samples, the pathologist creates a report on what was found. Your doctors will use this report to help manage your care. […] If the growth looks more abnormal, it may be called atypical hyperplasia. This can be either atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH). […] In ADH, the cells grow in an abnormal pattern and have some (but not all) of the features of ductal carcinoma in-situ (DCIS, which is a pre-cancer). This means that ADH is not yet a pre-cancer, although it is linked to an increased risk of getting breast cancer later on. […] If ADH is found on a needle biopsy, more tissue in that area usually needs to be removed to be sure that nothing more serious, such as DCIS or invasive cancer, is also present nearby.

• #8 Atypical Ductal Hyperplasia: Symptoms and Treatment

  https://www.verywellhealth.com/atypical-ductal-hyperplasia-of-the-breast-430683

  Atypical ductal hyperplasia (ADH) is an abnormal growth of cells in the breast. It is not breast cancer but is considered a precancerous condition. ADH is typically diagnosed with a biopsy after a suspicious area is found on an imaging test (e.g., mammogram or ultrasound) or during a physical exam. If found, atypical ductal hyperplasia will require close monitoring. […] Again, a breast biopsy is the only definitive test for diagnosing atypical ductal hyperplasia. A tissue sample may be obtained by either a core needle biopsy (needle localization biopsy during an ultrasound) or by an open surgical breast biopsy. […] When a biopsy finds atypical ductal hyperplasia, more tissue will be surgically removed and tested to make sure there is nothing else more serious in breast tissue. […] Though the following cannot confirm a diagnosis of atypical ductal hyperplasia, they may yield results that strengthen the possibility of one: Mammography: ADH often appears as a pattern of calcifications on a mammogram. […] Atypical ductal hyperplasia is an abnormal growth of cells in the milk ducts or lobes of the breast. It is considered precancerous. When a suspicious area is found on an image or during a physical exam it is diagnosed with a biopsy.

• #9 Atypical hyperplasia of the breast

  https://www.mymlc.com/health-information/diseases-and-conditions/a/atypical-hyperplasia-of-the-breast2/?section=Causes

  Atypical hyperplasia is usually discovered after a biopsy to evaluate a suspicious area found during a clinical breast exam or on an imaging test, such as a mammogram or ultrasound. […] To further evaluate atypical hyperplasia, your doctor may recommend surgery to remove a larger sample of tissue to look for breast cancer. A diagnosis of atypical hyperplasia may lead to a surgical biopsy (wide local excision or lumpectomy) to remove all of the affected tissue. The pathologist looks at the larger specimen for evidence of in situ or invasive cancer.

• #10 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Atypical-Hyperplasia.aspx

  Samples of tissue are removed during biopsy and sent to a lab for analysis by a pathologist. These samples are studied under a microscope which reveals the presence or absence of atypical hyperplasia. […] In case atypical hyperplasia is diagnosed, a surgical biopsy may be performed to remove the affected breast tissue. Further evaluation via surgery may be recommended by the doctor and this involves removal of a larger tissue sample from the breast and testing it for the presence of cancerous cells. The larger sample is analyzed by the pathologist for any evidence of invasive or non-invasive cancer.

• #11 Atypical Hyperplasia of the Breast: Follow-up and Management – The ObG Project

  https://www.obgproject.com/2017/04/19/atypical-hyperplasia-breast-follow-management/

  Atypical hyperplasia of the breast is a benign but high-risk condition that can be either ductal (ADH) or lobular (ALH); these occur with equal frequency and together are found in about 10% of breast biopsies. […] Either entity confers a long-term risk of breast cancer that approaches 30% at 25 years of follow-up. […] Surgically excise atypical hyperplasia when found on a core-needle biopsy. […] Necessary to avoid missing invasive cancer due to sampling error. […] DCIS or invasive cancer found in 10 to 20% of cases. […] Current breast cancer risk assessment models perform poorly among women with atypical hyperplasia. […] Atypical hyperplasia associated with a relative risk of approximately 4 for future breast cancer. […] Follow-up screening recommendations include annual mammography, breast awareness, and clinical encounter every 6 to 12 months.

• #12 Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0967-1

  ADH is usually first identified in a core needle biopsy (CNB), and first designated as a B3 lesion: i.e., of uncertain malignant potential of the breast. […] The management of patients diagnosed with ADH on CNB varies not only because of the initial biopsy type/size but also because of the variable reported upgrade rate. […] Upgrade of ADH refers to the finding of cancer (DCIS/IDC) in the surgical excision biopsy that was not present in the CNB. […] One very recent review stated that 22-65% of ADH diagnosed by CNB were upgraded to carcinoma. […] Given the high upgrade rate, it is not surprising that the majority of clinicians suggest a surgical excision after ADH diagnosis on CNB to rule out concomitant malignancy. […] Thus, the recommendation and current clinical practice is to perform an open surgical excision on all ADH diagnosed on CNB or VAB unless ADH is a single focus.

• #13 Atypical ductal hyperplasia – Wikipedia

  https://en.wikipedia.org/wiki/Atypical_ductal_hyperplasia

  The rate at which breast cancer (ductal carcinoma in situ or invasive mammary carcinoma (all breast cancer except DCIS and LCIS)) is found at the time of a surgical (excisional) biopsy, following the diagnosis of ADH on a core (needle) biopsy varies considerably from hospital-to-hospital (range 4-54%). […] In two large studies, the conversion of an ADH on core biopsy to breast cancer on surgical excision, known as „up-grading”, is approximately 30%.

• #14

  https://www.cancervic.org.au/cancer-information/screening/breasts-health/atypical-ductal-hyperplasia

  If you’ve been diagnosed with ADH, you’ll need expert advice on the treatment and follow-up that’s best for you. […] You may have been diagnosed with ADH after having a routine mammogram. On a mammogram, ADH can appear as a particular pattern of tiny calcifications. […] A core needle biopsy will be suggested. Under local anaesthetic, the doctor removes a sliver of tissue and then sends this to a pathologist. The diagnosis may also be made by surgical (open) biopsy. […] Alternatively, you may be diagnosed with ADH after you’ve noticed a breast problem of some kind. […] A mammogram and/or ultrasound is often the first step, followed by a core needle biopsy. Some of the cells removed may then reveal ADH. […] In most women ADH is harmless and won’t cause any problems in the future. […] However, in a few women with ADH, breast cancer can occur at a later date in the same breast or in the other one. […] With regular follow-up, any breast cancer that does develop is likely to be found early. […] The follow-up usually advised for women with ADH is an annual mammogram and a physical breast examination by a doctor.

• #15 Atypical Ductal Hyperplasia: Symptoms and Treatment

  https://www.verywellhealth.com/atypical-ductal-hyperplasia-of-the-breast-430683

  Atypical ductal hyperplasia (ADH) is an abnormal growth of cells in the breast. It is not breast cancer but is considered a precancerous condition. ADH is typically diagnosed with a biopsy after a suspicious area is found on an imaging test (e.g., mammogram or ultrasound) or during a physical exam. If found, atypical ductal hyperplasia will require close monitoring. […] Again, a breast biopsy is the only definitive test for diagnosing atypical ductal hyperplasia. A tissue sample may be obtained by either a core needle biopsy (needle localization biopsy during an ultrasound) or by an open surgical breast biopsy. […] When a biopsy finds atypical ductal hyperplasia, more tissue will be surgically removed and tested to make sure there is nothing else more serious in breast tissue. […] Though the following cannot confirm a diagnosis of atypical ductal hyperplasia, they may yield results that strengthen the possibility of one: Mammography: ADH often appears as a pattern of calcifications on a mammogram. […] Atypical ductal hyperplasia is an abnormal growth of cells in the milk ducts or lobes of the breast. It is considered precancerous. When a suspicious area is found on an image or during a physical exam it is diagnosed with a biopsy.

• #16 Atypical ductal hyperplasia – Benign lesion with malignant potential: A case report – International Journal of Case Reports and Images (IJCRI)

  https://www.ijcasereportsandimages.com/archive/article-full-text/101225Z01KI2021

  Atypical breast hyperplasia is a precancerous lesion with a high risk of invasive carcinoma. […] The diagnosis is based on a range of clinical, radiological, and histological arguments. […] Atypical ductal hyperplasia is characterized by the proliferation of dysplastic or monotonic epithelial cells of an endoluminal clonal nature. […] The atypical character of hyperplasia is confirmed by the absence of anti Ck5/6 immunolabeling in the immunohistochemical study. […] Atypical ductal hyperplasia lesions are difficult to detect on breast ultrasound which may show a hypoechogenic, oval, circumscribed, or indistinct mass. […] Ultrasound-guided percutaneous microbiopsy using an automatic needle (1114 Gauge) is the most common way to make the diagnosis. […] The treatment of atypical ductal hyperplasia is based on surgical excision with anatomopathological study in order to exclude the presence of an underlying carcinoma. […] Atypical ductal hyperplasia is an important predictor of breast cancer development.

• #17 Case: Atypical Ductal Hyperplasia – Radiology | UCLA Health

  https://www.uclahealth.org/departments/radiology/education/breast-imaging-teaching-resources/cases/atypical-ductal-hyperplasia

  Atypical ductal hyperplasia (ADH) is a non-malignant but high-risk lesion associated with progression to more advanced neoplasms including ductal carcinoma in situ (DCIS) and invasive carcinoma, and as a marker for the development of additional breast cancer. […] Atypical ductal hyperplasia is usually found incidentally on routine mammograms or breast MRI screenings. […] The pathologic definition of ADH is that of a single clonal intraductal epithelial cell proliferation that partially or fills 2 membrane-bound ductal spaces, or occupies 2 mm in maximum dimension. […] Studies suggest surgical upgrade rates to DCIS or invasive carcinoma of up to 22-65% for biopsy-proven ADH. Thus, surgical excision is recommended for cases of ADH found on core needle biopsy. […] The prognosis usually depends on the final excisional biopsy results.

• #18 Atypical Breast Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK470258/

  Atypical hyperplasia of the breast is defined as abnormal epithelial proliferative breast lesions that are not qualitatively or quantitatively abnormal enough to be classified as carcinoma in situ. Atypical hyperplasia is a premalignant condition and may occur in either ductal or lobular epithelium. […] Atypical hyperplasia cannot be identified on imaging but can be found on histopathologic examination of breast biopsy or excisions performed for other mammographic findings such as calcifications or other worrisome lesions seen on imaging. […] Atypical hyperplasia lesions are pre-malignant. Many authorities believe the patient should undergo complete surgical excision to exclude malignancy and prevent the development of advanced neoplasia if found on a breast biopsy. Surgical excision for core biopsies that show ADH is considered standard of care.

• #19 Breast Hyperplasia (Ductal or Lobular) | Benign Conditions | American Cancer Society

  https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/hyperplasia-of-the-breast-ductal-or-lobular.html

  Hyperplasia can be described as either usual or atypical, based on how the cells look under a microscope. […] In atypical hyperplasia (or hyperplasia with atypia), the cells look more distorted and abnormal. This can be either atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH). […] Hyperplasia doesn’t usually cause a lump that can be felt, but it can sometimes cause changes that can be seen on a mammogram. It’s diagnosed by doing a biopsy, during which a hollow needle or surgery is used to take out some of the abnormal breast tissue for testing. […] Atypical hyperplasia (either ADH or ALH): The risk of breast cancer is about 4 to 5 times higher than that of a woman with no breast abnormalities. More details about pathology reports showing atypical hyperplasia can be found in Understanding Your Pathology Report: Atypical Hyperplasia.

• #20 Atypical hyperplasia of the breast – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/symptoms-causes/syc-20369773

  Atypical hyperplasia is thought to be a very early step in the process that turns healthy cells into cancer cells. In theory, if atypical hyperplasia cells are allowed to continue growing, they could get more DNA changes and become cancer cells. More research is needed to understand how this happens. […] Both types of atypical hyperplasia increase the risk of breast cancer. Treatment for both types is similar. […] If you’ve been diagnosed with atypical hyperplasia of the breast, you have an increased risk of getting breast cancer in the future. The risk of breast cancer in those with atypical hyperplasia is about four times higher than in those who don’t have atypical hyperplasia. The risk is similar for atypical ductal hyperplasia and atypical lobular hyperplasia. […] Studies of women with atypical hyperplasia have found that the risk of breast cancer increases over time. At 25 years after diagnosis, about 30% of women with atypical hyperplasia may have breast cancer. Put another way, for every 100 women diagnosed with atypical hyperplasia, 30 can be expected to have breast cancer 25 years after diagnosis. And 70 will not develop breast cancer. […] It’s not clear whether there’s anything that can prevent atypical hyperplasia of the breast. The same things that help lower the risk of breast cancer may help lower the risk of atypical hyperplasia.

• #21 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Biopsy samples taken from your breast are studied by a doctor with special training, called a pathologist. After testing the samples, the pathologist creates a report on what was found. Your doctors will use this report to help manage your care. […] If the growth looks more abnormal, it may be called atypical hyperplasia. This can be either atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH). […] In ADH, the cells grow in an abnormal pattern and have some (but not all) of the features of ductal carcinoma in-situ (DCIS, which is a pre-cancer). This means that ADH is not yet a pre-cancer, although it is linked to an increased risk of getting breast cancer later on. […] If ADH is found on a needle biopsy, more tissue in that area usually needs to be removed to be sure that nothing more serious, such as DCIS or invasive cancer, is also present nearby.

• #22 Atypical Ductal Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562244/

  Atypical ductal hyperplasia (ADH) is a pathology finding, usually found incidentally on biopsy of the breast. ADH is associated with an increased risk of breast cancer and therefore classified as high risk lesion but not precursor lesion – the distinction being the increased risk of breast cancer can be anywhere in the breasts and not limited to the area of the ADH. […] Atypical ductal hyperplasia (ADH) is a pathologic finding in breast tissue. Atypical ductal hyperplasia is usually identified incidentally on specimens obtained by needle biopsy prompted by abnormal findings on mammography. Atypical ductal hyperplasia correlates with an increased risk of breast cancer and therefore classified as a „high risk” lesion but is not a „precursor” lesion – the distinction being the breast cancer associated with ADH can occur anywhere in the breasts and not only in the area of the ADH.

• #23 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Because having ADH increases your risk of breast cancer later on, your doctor may recommend more frequent follow up (with breast exams and imaging tests such as mammograms), as well as taking steps to lower your breast cancer risk, such as making lifestyle changes and taking medicine to help reduce your risk. […] ALH is an abnormal growth of cells within lobules of the breast that is linked with an increased risk of breast cancer. […] Because having ALH increases your risk of breast cancer later on, your doctor may recommend more frequent follow up (with breast exams and imaging tests such as mammograms), as well as taking steps to lower your breast cancer risk, such as making lifestyle changes and taking medicine to help reduce your risk.

• #24 Atypical Lobular Hyperplasia and Risk of Breast Cancer

  https://www.verywellhealth.com/atypical-lobular-hyperplasia-of-the-breast-430684

  Atypical lobular hyperplasia (ALH) is the abnormal growth of cells in the milk-producing glands of the breast (known as lobules). ALH specifically affects epithelial cells lining the walls of lobules. […] ALH is a precancerous condition that could lead to the earliest stage of breast cancer, known as ductal carcinoma in situ (DCIS). Because the risk of cancer is increased if you have ALH, you would need to undergo routine breast cancer screening. […] This article explains the symptoms and causes of atypical lobular hyperplasia, including how it is diagnosed and treated. It also describes the odds of getting breast cancer if diagnosed with ALH. […] Atypical lobular hyperplasia is a high-risk, precancerous lesion that can evolve into ductal carcinoma in situ (DCIS). […] Research suggests that the risk of developing breast cancer is as high as 20% if you have been diagnosed with ALH.

• #25 Atypical hyperplasia of the breast – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/symptoms-causes/syc-20369773

  Atypical hyperplasia is thought to be a very early step in the process that turns healthy cells into cancer cells. In theory, if atypical hyperplasia cells are allowed to continue growing, they could get more DNA changes and become cancer cells. More research is needed to understand how this happens. […] Both types of atypical hyperplasia increase the risk of breast cancer. Treatment for both types is similar. […] If you’ve been diagnosed with atypical hyperplasia of the breast, you have an increased risk of getting breast cancer in the future. The risk of breast cancer in those with atypical hyperplasia is about four times higher than in those who don’t have atypical hyperplasia. The risk is similar for atypical ductal hyperplasia and atypical lobular hyperplasia. […] Studies of women with atypical hyperplasia have found that the risk of breast cancer increases over time. At 25 years after diagnosis, about 30% of women with atypical hyperplasia may have breast cancer. Put another way, for every 100 women diagnosed with atypical hyperplasia, 30 can be expected to have breast cancer 25 years after diagnosis. And 70 will not develop breast cancer. […] It’s not clear whether there’s anything that can prevent atypical hyperplasia of the breast. The same things that help lower the risk of breast cancer may help lower the risk of atypical hyperplasia.

• #26 Atypical hyperplasia of the breast – Hancock Health

  https://www.hancockhealth.org/mayo-health-library/atypical-hyperplasia-of-the-breast/

  If youve been diagnosed with atypical hyperplasia of the breast, you have an increased risk of getting breast cancer in the future. The risk of breast cancer in those with atypical hyperplasia is about four times higher than in those who dont have atypical hyperplasia. […] Atypical hyperplasia of the breast is most often diagnosed during a breast biopsy. A breast biopsy is a procedure to remove a sample of breast tissue for testing. Its often done if something concerning is found during a clinical breast exam or on an imaging test, such as a mammogram or an ultrasound. […] Treatment for atypical hyperplasia of the breast may involve surgery to remove the atypical cells. Not everyone needs surgery. Your healthcare team might recommend more-frequent breast cancer screening to watch for signs of breast cancer. You also might consider medicine to lower your risk of breast cancer.

• #27 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Biopsy samples taken from your breast are studied by a doctor with special training, called a pathologist. After testing the samples, the pathologist creates a report on what was found. Your doctors will use this report to help manage your care. […] If the growth looks more abnormal, it may be called atypical hyperplasia. This can be either atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH). […] In ADH, the cells grow in an abnormal pattern and have some (but not all) of the features of ductal carcinoma in-situ (DCIS, which is a pre-cancer). This means that ADH is not yet a pre-cancer, although it is linked to an increased risk of getting breast cancer later on. […] If ADH is found on a needle biopsy, more tissue in that area usually needs to be removed to be sure that nothing more serious, such as DCIS or invasive cancer, is also present nearby.

• #28 Pathology Outlines – Atypical ductal hyperplasia

  https://www.pathologyoutlines.com/topic/breastadh.html

  Intraductal clonal epithelial cell proliferation with similar histologic features to (but insufficient involvement or volume for the diagnosis of) low grade ductal carcinoma in situ (DCIS) […] Intraductal clonal epithelial cell proliferation with cytologic and morphologic features similar to low grade ductal carcinoma in situ […] Differentiated from low grade ductal carcinoma in situ by size (≤ 2 mm) or space occupied by clonal cells (≤ 2 spaces or only portion of involved space) […] 5 – 20% of breast biopsies (StatPearls: Atypical Breast Hyperplasia [Accessed 19 November 2019]) […] Recent radiological pathological concordance series have shown that biopsy diagnosed atypical ductal hyperplasia (ADH) has an upgrade rate of 10 – 20% to DCIS or invasive carcinoma […] Higher risk with younger age, BRCA1 / BRCA2 mutations, family history, higher number of separate foci (overall volume), extent of lobular involution (complete / partial) correlated with age

• #29 Atypical Hyperplasia and Breast Cancer Risk with Moose and Doc

  https://breast-cancer.ca/atyp-hyp/

  But even if this is the case, if the subsequent histological work-up does not indicate sufficient malignancy indicators, the lesion will still be described as ADH. […] Also, a lesion with all the features of DCIS but measuring less than 2mm will also be classified as ADH. […] Atypical cytologic (cell study) appearance is the most important feature when separating ADH from DH. […] Doctors usually make a diagnosis of ADH depending on three main components. […] These are the architectural pattern, disease extent, and cytology. […] ADH develops as a uniform population of round, polygonal or cuboidal hyperchromatic cells, of a small to medium size. […] Cells mitosis are very infrequent. […] Even though any sort of unexpected cellular proliferation can be considered as a probable risk factor for breast cancer.

• #30 Case: Atypical Ductal Hyperplasia – Radiology | UCLA Health

  https://www.uclahealth.org/departments/radiology/education/breast-imaging-teaching-resources/cases/atypical-ductal-hyperplasia

  Atypical ductal hyperplasia (ADH) is a non-malignant but high-risk lesion associated with progression to more advanced neoplasms including ductal carcinoma in situ (DCIS) and invasive carcinoma, and as a marker for the development of additional breast cancer. […] Atypical ductal hyperplasia is usually found incidentally on routine mammograms or breast MRI screenings. […] The pathologic definition of ADH is that of a single clonal intraductal epithelial cell proliferation that partially or fills 2 membrane-bound ductal spaces, or occupies 2 mm in maximum dimension. […] Studies suggest surgical upgrade rates to DCIS or invasive carcinoma of up to 22-65% for biopsy-proven ADH. Thus, surgical excision is recommended for cases of ADH found on core needle biopsy. […] The prognosis usually depends on the final excisional biopsy results.

• #31 Atypical Lobular Hyperplasia and Risk of Breast Cancer

  https://www.verywellhealth.com/atypical-lobular-hyperplasia-of-the-breast-430684

  Imaging and a tissue biopsy are needed to confirm an atypical lobular hyperplasia diagnosis. […] Breast biopsy: This is the definitive method of diagnosis of ALH. Under the microscope, epithelial cells will look abnormal and be tightly packed and haphazardly arranged. […] ALH is found in 5% to 20% of breast biopsies. […] Many cases of ALH do not require treatment and will instead be monitored regularly to check for any changes in breast tissues. This is called active surveillance. […] Some people may be advised to undergo surgery, either in the form of a wide local excision (used to remove all the affected tissues along with a small margin of unaffected tissues) or a lumpectomy (if an actual lump is present). […] ALH is a type of precancer in which abnormal cells develop in the milk-producing glands of the breast. ALH can lead to an early-stage cancer called ductal carcinoma in situ (DCIS) in up to one of every five people with ALH. […] ALH often does not require treatment but will instead be regularly monitored with a screening mammogram and/or a breast MRI. Some people at high risk of breast cancer may have the ALH lesions removed just to be safe.

• #32 Atypical Hyperplasia on Breast Biopsy may be Misinterpreted by Experienced Pathologists | EBM Focus

  https://www.ebsco.com/clinical-decisions/dynamed-solutions/about/ebm-focus/atypical-hyperplasia-breast-biopsy-may-be

  Atypical hyperplasia 48% 35% 17% […] the concordance rate drops considerably for atypical hyperplasia, with most misinterpretations resulting in an underinterpretation of the disease as a benign biopsy. […] The results of this study suggest that while pathologists generally agree upon interpretation of invasive carcinoma samples, their interpretations of precancerous lesions may be more variable. […] Decreasing variability in biopsy diagnosis is important as overinterpretation may lead to unnecessary treatment and underinterpretation may withhold necessary treatments or decrease surveillance in patients with precancerous lesions.

• #33 Atypical hyperplasia of the breast – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/symptoms-causes/syc-20369773

  Atypical hyperplasia is thought to be a very early step in the process that turns healthy cells into cancer cells. In theory, if atypical hyperplasia cells are allowed to continue growing, they could get more DNA changes and become cancer cells. More research is needed to understand how this happens. […] Both types of atypical hyperplasia increase the risk of breast cancer. Treatment for both types is similar. […] If you’ve been diagnosed with atypical hyperplasia of the breast, you have an increased risk of getting breast cancer in the future. The risk of breast cancer in those with atypical hyperplasia is about four times higher than in those who don’t have atypical hyperplasia. The risk is similar for atypical ductal hyperplasia and atypical lobular hyperplasia. […] Studies of women with atypical hyperplasia have found that the risk of breast cancer increases over time. At 25 years after diagnosis, about 30% of women with atypical hyperplasia may have breast cancer. Put another way, for every 100 women diagnosed with atypical hyperplasia, 30 can be expected to have breast cancer 25 years after diagnosis. And 70 will not develop breast cancer. […] It’s not clear whether there’s anything that can prevent atypical hyperplasia of the breast. The same things that help lower the risk of breast cancer may help lower the risk of atypical hyperplasia.

• #34 Atypical hyperplasia of the breast | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/non-cancerous-conditions/atypical-hyperplasia

  Hyperplasia is an increase in the number of normal cells growing in a tissue. Atypical hyperplasia means that the cells that are increasing in a tissue are abnormal. […] Having atypical hyperplasia increases the risk for breast cancer. This risk is even higher in women who have a family history of breast cancer or who are diagnosed with atypical hyperplasia before they reach menopause. Breast cancer is more likely to start in the breast where atypical hyperplasia is found. The risk of developing breast cancer is greatest 10-15 years after atypical hyperplasia is diagnosed. The risk begins to go down after 15 years. […] Women with atypical hyperplasia should talk to their doctor about a personal plan of testing for breast cancer, including regular mammography. […] Atypical hyperplasia of the breast does not cause any symptoms. It is usually found during screening mammography. […] Women with atypical hyperplasia should talk to their healthcare team about the benefits and possible risks of taking SERMs to reduce their risk of breast cancer.

• #35 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  The younger a woman is when she receives a diagnosis of atypical ductal hyperplasia, the more likely it is that breast cancer will develop in her lifetime; however, if women with atypical ductal hyperplasia take medication to prevent breast cancer, their risk of developing breast cancer may be reduced by over 40% and up to approximately 80%. […] Atypical hyperplasia confers an absolute risk of later breast cancer of 30% at 25 years of follow-up. […] Once a woman is diagnosed with atypical hyperplasia, she has a cumulative incidence of breast cancer (either ductal carcinoma in situ or invasive cancer) of 30% over the next 25 years, based on the Mayo Clinic Cohort study. […] The risk of breast cancer is higher in those diagnosed with atypical hyperplasia at a younger age and in those with a greater number of foci containing atypia.

• #36

  https://www.kwongbreastclinic.com.sg/breast-health/benign-breast-conditions/atypical-hyperplasia/

  Atypical hyperplasia is an accumulation of abnormal cells in the breast and it is a risk factor for developing breast cancer. […] A biopsy of the abnormal area seen on mammogram may be recommended. This may be done using a needle biopsy or by open biopsy. An open biopsy allows more tissue to be examined and in about 25 percent of cases, an early cancer may be found. […] There is an increased risk of developing breast cancer in the future. It is about four times the lifetime risk. […] At 5 years after the diagnosis of atypical hyperplasia, 7 percent of the women may develop breast cancer. At 10 years after the diagnosis, 13 percent may develop breast cancer and at 25 years after the diagnosis, about 30 percent may develop breast cancer. […] Women with atypical hyperplasia should continue with monthly breast self-examinations in order to detect any early breast changes as well as consider annual mammograms, in view of the increased risk.

• #37 Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening – The ASCO Post

  https://ascopost.com/issues/february-25-2015/atypical-hyperplasia-as-a-predictor-of-future-breast-cancer-focus-on-chemoprevention-and-screening.aspx

  The National Comprehensive Cancer Network (NCCN) recommends annual MRI screening for women with a lifetime risk greater than 20%, as defined by models that are dependent largely on family history, the authors added, but for women with atypical hyperplasia specifically, they state that there is insufficient evidence to make recommendations for or against MRI screening. […] Whether or not guidelines are revised to incorporate a recommendation to use MRI to screen women diagnosed with atypical hyperplasia, physicians should be discussing it with their patients as a possibility, Dr. Degnim advised. […] Existing risk prediction models, such as the Breast Cancer Risk Assessment Tool (BCRAT) and the International Breast Cancer Intervention Study (IBIS) model, perform poorly among women with atypical hyperplasia, according to the report.

• #38 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  The Breast Cancer Risk Assessment Tool, which is available online and widely used by practitioners to counsel women on their risk, significantly underestimates breast cancer risk in women with atypical hyperplasia. […] 97% of atypical ductal hyperplasia and 88% of atypical lobular hyperplasia has estrogen receptor staining, meaning it is stimulated by estrogen. […] Because of this, medications called selective estrogen receptor modulators (for example, tamoxifen and raloxifene) and aromatase inhibitors (for example, exemestane, anastrozole, and letrozole) have been shown in clinical trials to effectively reduce the risk of breast cancer associated with these lesions. […] A recent meta-analysis of selective estrogen receptor modulator trials found a 38% relative reduction in the risk of breast cancer in those taking the medication.

• #39 Atypical Breast Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK470258/

  It is important to note that while surgical excision after identifying atypical hyperplasia in a core biopsy is generally considered appropriate, some disagreement persists regarding the management of high-risk lesions in certain cases. Proper management will depend on discussing all factors with the patient, and this includes a review of current treatment modalities and recommendations, patient risk factors, careful radiologic/pathologic correlation, and the overall clinical picture.

• #40 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Biopsy samples taken from your breast are studied by a doctor with special training, called a pathologist. After testing the samples, the pathologist creates a report on what was found. Your doctors will use this report to help manage your care. […] If the growth looks more abnormal, it may be called atypical hyperplasia. This can be either atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH). […] In ADH, the cells grow in an abnormal pattern and have some (but not all) of the features of ductal carcinoma in-situ (DCIS, which is a pre-cancer). This means that ADH is not yet a pre-cancer, although it is linked to an increased risk of getting breast cancer later on. […] If ADH is found on a needle biopsy, more tissue in that area usually needs to be removed to be sure that nothing more serious, such as DCIS or invasive cancer, is also present nearby.

• #41 Atypical Ductal Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562244/

  It is important to know the type of specimen in which the ADH is identified because the lesion’s management depends on it. […] If atypical ductal hyperplasia is found on core needle biopsy, additional tissue is necessary by excisional biopsy. […] If, however, ADH alone is diagnosed on an excisional biopsy, no additional surgery is required, even if there are positive margins because ADH is a high-risk lesion, but it is not a pre-cancerous or cancerous lesion. […] Once identifying atypical ductal hyperplasia as the diagnosis and ruling out breast carcinoma, it is essential to address risk reduction strategies. […] Atypical ductal hyperplasia has a history of surgical overtreatment. If diagnosed on core needle biopsy, a more extensive excisional biopsy is required to rule out breast carcinoma.

• #42 Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0967-1

  This practice would certainly overtreat the majority of women diagnosed with ADH and clearly demonstrates the need to identify a robust biomarker to avoid unnecessary surgery and optimal management. […] Unfortunately, risk prediction following ADH diagnosis is controversial, and counseling and further screening for these women diagnosed with ADH are therefore probably not adequate. […] The complexities of analyzing focality, calcification, and atypia in terms of how these are measured emphasizes the importance of understanding the breast biology, as well as the precursor versus risk indicator status of ADH. […] Overall, the various limitations of all the previous studies discussed in this review (small sample size, lacking careful selection of ADH with and without carcinoma, low resolution methodology, etc.) need to be overcome in any future study of ADH.

• #43

  https://www.archbreastcancer.com/index.php/abc/article/view/512

  Atypical ductal hyperplasia (ADH) is a high-risk breast lesion. […] NCCN guidelines recommend surgical excision for patients with atypical ductal hyperplasia (ADH) on percutaneous biopsy. […] When these women undergo surgical excision for ADH identified on percutaneous biopsy, the upgrade rate to underlying malignancy ranges in the literature anywhere from 4% to 54%. […] Multiple studies have been performed in an attempt to stratify which patients have the lowest risk of underlying malignancy and may therefore avoid surgical excision. […] We sought to identify low-risk features of ADH to define patients who may benefit from active monitoring over surgical excision. […] Overall upgrade rate was low in this contemporary cohort. Patients at lowest risk for upgrade had all 4 low-risk features and could be safely offered active monitoring over surgical excision.

• #44 Understanding Your Pathology Report: Atypical Hyperplasia (Breast) | American Cancer Society

  https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/atypical-hyperplasia.html

  Because having ADH increases your risk of breast cancer later on, your doctor may recommend more frequent follow up (with breast exams and imaging tests such as mammograms), as well as taking steps to lower your breast cancer risk, such as making lifestyle changes and taking medicine to help reduce your risk. […] ALH is an abnormal growth of cells within lobules of the breast that is linked with an increased risk of breast cancer. […] Because having ALH increases your risk of breast cancer later on, your doctor may recommend more frequent follow up (with breast exams and imaging tests such as mammograms), as well as taking steps to lower your breast cancer risk, such as making lifestyle changes and taking medicine to help reduce your risk.

• #45 Breast Cancer Risk: Usual and Atypical Hyperplasia | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/hyperplasia-and-other-benign-breast-conditions/

  Atypical hyperplasia is less common than usual hyperplasia. […] Women with atypical hyperplasia have about 3 to 5 times the breast cancer risk of women without a proliferative breast condition. […] For women with atypical hyperplasia who also have a 20% or greater lifetime risk of invasive breast cancer, there are special breast cancer screening recommendations. […] The NCCN strongly recommends women with atypical hyperplasia take a risk-reducing drug (such as tamoxifen) to lower their risk of developing breast cancer. […] These drugs can lower the risk of breast cancer in women with atypical hyperplasia by about 86%.

• #46 Atypical Breast Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK470258/

  It is important to note that while surgical excision after identifying atypical hyperplasia in a core biopsy is generally considered appropriate, some disagreement persists regarding the management of high-risk lesions in certain cases. Proper management will depend on discussing all factors with the patient, and this includes a review of current treatment modalities and recommendations, patient risk factors, careful radiologic/pathologic correlation, and the overall clinical picture.

• #47 Navigating breast health: a comprehensive approach to atypical ductal hyperplasia of the breast management and surveillance

  https://www.explorationpub.com/Journals/em/Article/1001205

  ADH carries a risk of unsampled malignancy. […] The average latency period for progressing to invasive cancer is around 10 years. […] ADH is associated with a 3 to 5-fold increased relative risk for breast cancer, approximately 1% absolute risk per year for at least 25 years, and a 10-20% absolute lifetime risk of invasive carcinoma development. […] The factors found to be most likely associated with increased risk for upgrade include multiple duct involvement, suspicion for DCIS, ADH found on another high-risk lesion on CNB, and diffuse calcifications on subsequent excision biopsy. […] The current standard of care for ADH is surgical excision to avoid missing coexisting IBC. […] According to National Comprehensive Cancer Network (NCCN) recommendations, patients diagnosed with ADH should be offered lifetime surveillance.

• #48

  https://link.springer.com/article/10.1007/s44326-024-00011-4

  Atypical hyperplasia corresponds to an abnormal proliferation of the breast that does not meet the criteria of ductal carcinoma in situ (DCIS). […] Atypical hyperplasia has two distinct entities: ALH and ADH. ALH is a rare, occurring in 1% of women. […] This review of ALH discusses the pathology, imaging features and its management with other atypical high-risk breast lesions. […] The most common presentation of ALH is grouped amorphous calcifications. […] The risk of upgrade to cancer involving ALH is variable in the literature. […] Considering published data with small cohorts, ALH management remains controversial given the risks of over and under treatment. […] The American Society of Breast Surgeons recommends surveillance in a patient with ALH if the following criteria are met: Radiological-pathological correlation, No associated lesion(s) that would require surgical excision, Small-volume lesion. […] ALH is a high-risk lesion that can display heterogeneity on imaging. Its management continues to evolve with an emphasis on radiological-pathological correlation and the need for the assessment of a family and personal history of breast cancer in the patient.

• #49

  https://link.springer.com/article/10.1007/s44326-024-00011-4

  Atypical hyperplasia corresponds to an abnormal proliferation of the breast that does not meet the criteria of ductal carcinoma in situ (DCIS). […] Atypical hyperplasia has two distinct entities: ALH and ADH. ALH is a rare, occurring in 1% of women. […] This review of ALH discusses the pathology, imaging features and its management with other atypical high-risk breast lesions. […] The most common presentation of ALH is grouped amorphous calcifications. […] The risk of upgrade to cancer involving ALH is variable in the literature. […] Considering published data with small cohorts, ALH management remains controversial given the risks of over and under treatment. […] The American Society of Breast Surgeons recommends surveillance in a patient with ALH if the following criteria are met: Radiological-pathological correlation, No associated lesion(s) that would require surgical excision, Small-volume lesion. […] ALH is a high-risk lesion that can display heterogeneity on imaging. Its management continues to evolve with an emphasis on radiological-pathological correlation and the need for the assessment of a family and personal history of breast cancer in the patient.

• #50 Navigating breast health: a comprehensive approach to atypical ductal hyperplasia of the breast management and surveillance

  https://www.explorationpub.com/Journals/em/Article/1001205

  ADH carries a risk of unsampled malignancy. […] The average latency period for progressing to invasive cancer is around 10 years. […] ADH is associated with a 3 to 5-fold increased relative risk for breast cancer, approximately 1% absolute risk per year for at least 25 years, and a 10-20% absolute lifetime risk of invasive carcinoma development. […] The factors found to be most likely associated with increased risk for upgrade include multiple duct involvement, suspicion for DCIS, ADH found on another high-risk lesion on CNB, and diffuse calcifications on subsequent excision biopsy. […] The current standard of care for ADH is surgical excision to avoid missing coexisting IBC. […] According to National Comprehensive Cancer Network (NCCN) recommendations, patients diagnosed with ADH should be offered lifetime surveillance.

• #51

  https://archbreastcancer.com/index.php/abc/article/view/512

  Atypical hyperplasia carries a 4-fold increase in future breast cancer risk. Atypical ductal hyperplasia (ADH) is a high-risk breast lesion. […] NCCN guidelines recommend surgical excision for patients with atypical ductal hyperplasia (ADH) on percutaneous biopsy. […] The only significant low-risk pathologic feature was the lack of micropapillary features (P=0.10). […] Patients at lowest risk for upgrade had all 4 low-risk features and could be safely offered active monitoring over surgical excision. […] The lowest rate of upgrade was in those who had an imaging abnormality 1cm with 50% removed by the stereotactic biopsy and had 3 foci of ADH without associated with micropapillary features. […] The loss of one low-risk feature is associated with a 129% increase in the odds of upgrade (OR=2.29, 95% CI 1.35, 4.15).

• #52

  https://archbreastcancer.com/index.php/abc/article/view/512

  Atypical hyperplasia carries a 4-fold increase in future breast cancer risk. Atypical ductal hyperplasia (ADH) is a high-risk breast lesion. […] NCCN guidelines recommend surgical excision for patients with atypical ductal hyperplasia (ADH) on percutaneous biopsy. […] The only significant low-risk pathologic feature was the lack of micropapillary features (P=0.10). […] Patients at lowest risk for upgrade had all 4 low-risk features and could be safely offered active monitoring over surgical excision. […] The lowest rate of upgrade was in those who had an imaging abnormality 1cm with 50% removed by the stereotactic biopsy and had 3 foci of ADH without associated with micropapillary features. […] The loss of one low-risk feature is associated with a 129% increase in the odds of upgrade (OR=2.29, 95% CI 1.35, 4.15).

• #53

  https://www.archbreastcancer.com/index.php/abc/article/view/512

  The lowest rate of upgrade was in those who had an imaging abnormality 1cm with 50% removed by the stereotactic biopsy and had 3 foci of ADH without associated with micropapillary features. […] Our study was able to demonstrate that the lowest risk for upgrade in our patient population are those with an imaging target of 1cm in size, 50% of the lesion removed by the percutaneous biopsy, 1-2 foci of ADH, and the absence of micropapillary features.

• #54

  https://archbreastcancer.com/index.php/abc/article/view/512

  Atypical hyperplasia carries a 4-fold increase in future breast cancer risk. Atypical ductal hyperplasia (ADH) is a high-risk breast lesion. […] NCCN guidelines recommend surgical excision for patients with atypical ductal hyperplasia (ADH) on percutaneous biopsy. […] The only significant low-risk pathologic feature was the lack of micropapillary features (P=0.10). […] Patients at lowest risk for upgrade had all 4 low-risk features and could be safely offered active monitoring over surgical excision. […] The lowest rate of upgrade was in those who had an imaging abnormality 1cm with 50% removed by the stereotactic biopsy and had 3 foci of ADH without associated with micropapillary features. […] The loss of one low-risk feature is associated with a 129% increase in the odds of upgrade (OR=2.29, 95% CI 1.35, 4.15).

• #55 Atypical ductal hyperplasia – Benign lesion with malignant potential: A case report – International Journal of Case Reports and Images (IJCRI)

  https://www.ijcasereportsandimages.com/archive/article-full-text/101225Z01KI2021

  Atypical breast hyperplasia is a precancerous lesion with a high risk of invasive carcinoma. […] The diagnosis is based on a range of clinical, radiological, and histological arguments. […] Atypical ductal hyperplasia is characterized by the proliferation of dysplastic or monotonic epithelial cells of an endoluminal clonal nature. […] The atypical character of hyperplasia is confirmed by the absence of anti Ck5/6 immunolabeling in the immunohistochemical study. […] Atypical ductal hyperplasia lesions are difficult to detect on breast ultrasound which may show a hypoechogenic, oval, circumscribed, or indistinct mass. […] Ultrasound-guided percutaneous microbiopsy using an automatic needle (1114 Gauge) is the most common way to make the diagnosis. […] The treatment of atypical ductal hyperplasia is based on surgical excision with anatomopathological study in order to exclude the presence of an underlying carcinoma. […] Atypical ductal hyperplasia is an important predictor of breast cancer development.

• #56 Atypical Hyperplasia

  https://cbcn.ca/en/atypical-hyperplasia

  Po zdiagnozowaniu atypowej hiperplazji może być przeprowadzony test E-kadheryny, aby określić, czy masz ADH czy ALH. […] Nie ma zauważalnych oznak ani objawów atypowej hiperplazji; może wystąpić ból piersi, ale jest to bardzo rzadkie. Nie można jej również wykryć podczas badania piersi ani obrazowania piersi. Chociaż atypowa hiperplazja może pojawić się na mammografii lub ultrasonografii jako skupiska mikrozwapnień, jedynym sposobem na jej zdiagnozowanie jest biopsja piersi. Biopsja ta jest zazwyczaj wykonywana jako test kontrolny po podejrzanym wyniku mammografii lub ultrasonografii.

• #57 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  The Breast Cancer Risk Assessment Tool, which is available online and widely used by practitioners to counsel women on their risk, significantly underestimates breast cancer risk in women with atypical hyperplasia. […] 97% of atypical ductal hyperplasia and 88% of atypical lobular hyperplasia has estrogen receptor staining, meaning it is stimulated by estrogen. […] Because of this, medications called selective estrogen receptor modulators (for example, tamoxifen and raloxifene) and aromatase inhibitors (for example, exemestane, anastrozole, and letrozole) have been shown in clinical trials to effectively reduce the risk of breast cancer associated with these lesions. […] A recent meta-analysis of selective estrogen receptor modulator trials found a 38% relative reduction in the risk of breast cancer in those taking the medication.

• #58 Atypical ductal hyperplasia – Benign lesion with malignant potential: A case report – International Journal of Case Reports and Images (IJCRI)

  https://www.ijcasereportsandimages.com/archive/article-full-text/101225Z01KI2021

  Atypical breast hyperplasia is a precancerous lesion with a high risk of invasive carcinoma. […] The diagnosis is based on a range of clinical, radiological, and histological arguments. […] Atypical ductal hyperplasia is characterized by the proliferation of dysplastic or monotonic epithelial cells of an endoluminal clonal nature. […] The atypical character of hyperplasia is confirmed by the absence of anti Ck5/6 immunolabeling in the immunohistochemical study. […] Atypical ductal hyperplasia lesions are difficult to detect on breast ultrasound which may show a hypoechogenic, oval, circumscribed, or indistinct mass. […] Ultrasound-guided percutaneous microbiopsy using an automatic needle (1114 Gauge) is the most common way to make the diagnosis. […] The treatment of atypical ductal hyperplasia is based on surgical excision with anatomopathological study in order to exclude the presence of an underlying carcinoma. […] Atypical ductal hyperplasia is an important predictor of breast cancer development.

• #59 Atypical ductal hyperplasia – Benign lesion with malignant potential: A case report – International Journal of Case Reports and Images (IJCRI)

  https://www.ijcasereportsandimages.com/archive/article-full-text/101225Z01KI2021

  Atypical breast hyperplasia is a precancerous lesion with a high risk of invasive carcinoma. […] The diagnosis is based on a range of clinical, radiological, and histological arguments. […] Atypical ductal hyperplasia is characterized by the proliferation of dysplastic or monotonic epithelial cells of an endoluminal clonal nature. […] The atypical character of hyperplasia is confirmed by the absence of anti Ck5/6 immunolabeling in the immunohistochemical study. […] Atypical ductal hyperplasia lesions are difficult to detect on breast ultrasound which may show a hypoechogenic, oval, circumscribed, or indistinct mass. […] Ultrasound-guided percutaneous microbiopsy using an automatic needle (1114 Gauge) is the most common way to make the diagnosis. […] The treatment of atypical ductal hyperplasia is based on surgical excision with anatomopathological study in order to exclude the presence of an underlying carcinoma. […] Atypical ductal hyperplasia is an important predictor of breast cancer development.

• #60 Atypical Ductal Hyperplasia | Tampa General Hospital

  https://www.tgh.org/institutes-and-services/conditions/atypical-ductal-hyperplasia-breast

  Atypical ductal hyperplasia (ADH) is a precancerous breast condition that occurs when abnormal cells build up in the lining of the ducts that carry milk from the milk-producing glands (lobules) to the nipple. […] However, because it is a marker for the future development of breast cancer, it should be periodically monitored by a breast cancer specialist. […] If ADH is suspected based on the results of an imaging scan or breast exam, a physician will typically order a biopsy to obtain a sample of the abnormal cells for microscopic evaluation by a pathologist. One option that is frequently used to diagnose atypical ductal hyperplasia is a stereotactic core needle biopsy. […] If a core biopsy reveals ADH, the physician may recommend an excisional biopsy to collect more tissue and rule out any associated cancer.

• #61 Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0967-1

  Atypical ductal hyperplasia (ADH) is a common diagnosis in the mammographic era and a significant clinical problem with wide variation in diagnosis and treatment. […] After a diagnosis of ADH on biopsy a proportion are upgraded to carcinoma upon excision; however, the remainder of patients are overtreated. […] While ADH is considered a non-obligate precursor of invasive carcinoma, the molecular taxonomy remains unknown. […] This article will review the definitions and variable management of the patients diagnosed with ADH as well as the current knowledge of the molecular landscape of ADH and its clonal relationship with ductal carcinoma in situ and invasive carcinoma. […] Molecular data of ADH remain sparse. […] Large prospective cohorts of pure ADH with clinical follow-up need to be evaluated at DNA, RNA, and protein levels in order to develop biomarkers of progression to carcinoma to guide management decisions.

• #62 Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0967-1

  This practice would certainly overtreat the majority of women diagnosed with ADH and clearly demonstrates the need to identify a robust biomarker to avoid unnecessary surgery and optimal management. […] Unfortunately, risk prediction following ADH diagnosis is controversial, and counseling and further screening for these women diagnosed with ADH are therefore probably not adequate. […] The complexities of analyzing focality, calcification, and atypia in terms of how these are measured emphasizes the importance of understanding the breast biology, as well as the precursor versus risk indicator status of ADH. […] Overall, the various limitations of all the previous studies discussed in this review (small sample size, lacking careful selection of ADH with and without carcinoma, low resolution methodology, etc.) need to be overcome in any future study of ADH.

• #63 Atypical Hyperplasia and Breast Cancer Risk with Moose and Doc

  https://breast-cancer.ca/atyp-hyp/

  Atypical ductal hyperplasia can not be considered as a obligate precursor to invasive ductal breast cancer. […] Some studies suggest that when atypical ductal hyperplasia is present in more than 2 foci in a core-needle biopsy specimen, there is a greater possibility of ductal carcinoma in situ. […] Furthermore, specialists believe that the micropapillary pattern of atypical ductal hyperplasia is also a more likely precursor for DCIS. […] There remains no clear, undisputed evidence that either hyperplasia without atypia and ADH are precursors to either DCIS or invasive carcinoma. […] When there is a suspicious area on mammogram, doctors will request a biopsy to evaluate the tissue, and this is usually when atypical hyperplasia is discovered. […] The surgeon removes tissue samples at biopsy and sends them for analysis by a pathologist.

• #64 Atypical Hyperplasia of the Breast: Follow-up and Management – The ObG Project

  https://www.obgproject.com/2017/04/19/atypical-hyperplasia-breast-follow-management/

  Atypical hyperplasia of the breast is a benign but high-risk condition that can be either ductal (ADH) or lobular (ALH); these occur with equal frequency and together are found in about 10% of breast biopsies. […] Either entity confers a long-term risk of breast cancer that approaches 30% at 25 years of follow-up. […] Surgically excise atypical hyperplasia when found on a core-needle biopsy. […] Necessary to avoid missing invasive cancer due to sampling error. […] DCIS or invasive cancer found in 10 to 20% of cases. […] Current breast cancer risk assessment models perform poorly among women with atypical hyperplasia. […] Atypical hyperplasia associated with a relative risk of approximately 4 for future breast cancer. […] Follow-up screening recommendations include annual mammography, breast awareness, and clinical encounter every 6 to 12 months.

• #65 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  Because studies show that the lifetime risk of breast cancer is greater than 20% for women with atypical hyperplasia, the role of annual MRI plus mammography surveillance is appropriate. […] Risk-reducing endocrine therapy should be discussed with patients because of increased lifetime risk of breast cancer, estimated at 1% per year.

• #66 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Atypical-Hyperplasia-and-Breast-Cancer-Risk.aspx

  According to National Comprehensive Cancer Network (NCCN) recommendations, women with atypical hyperplasia should have a clinical breast examination every 6 to 12 months after 30 years of age, and have a mammogram once a year starting at age 30 years. […] According to American Cancer Society (ACS) breast cancer screening recommendations, women diagnosed with atypical hyperplasia do not need clinical breast examination, but should have a mammogram every year and keep their health care providers up to date about their risk.

• #67 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Atypical-Hyperplasia-and-Breast-Cancer-Risk.aspx

  According to National Comprehensive Cancer Network (NCCN) recommendations, women with atypical hyperplasia should have a clinical breast examination every 6 to 12 months after 30 years of age, and have a mammogram once a year starting at age 30 years. […] According to American Cancer Society (ACS) breast cancer screening recommendations, women diagnosed with atypical hyperplasia do not need clinical breast examination, but should have a mammogram every year and keep their health care providers up to date about their risk.

• #68 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  Flat epithelial atypia without an associated high-risk lesion does not require discussion of risk-reducing endocrine therapy unless formal risk assessment using a model largely dependent on family history suggests otherwise. […] Atypical hyperplasia of the breast is a high-risk benign breast lesion that carries an increased lifetime risk for invasive breast cancer. […] For women with atypical hyperplasia, the cumulative breast cancer risk is approximately 1% per year. […] The American Cancer Society recommends magnetic resonance imaging (MRI) breast screening for patients with a calculated lifetime breast cancer risk of at least 20% based on IBIS. […] The American College of Radiology and National Comprehensive Cancer Network currently recommend that MRI screening be considered in addition to annual mammography for women with atypical hyperplasia.

• #69 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  Flat epithelial atypia without an associated high-risk lesion does not require discussion of risk-reducing endocrine therapy unless formal risk assessment using a model largely dependent on family history suggests otherwise. […] Atypical hyperplasia of the breast is a high-risk benign breast lesion that carries an increased lifetime risk for invasive breast cancer. […] For women with atypical hyperplasia, the cumulative breast cancer risk is approximately 1% per year. […] The American Cancer Society recommends magnetic resonance imaging (MRI) breast screening for patients with a calculated lifetime breast cancer risk of at least 20% based on IBIS. […] The American College of Radiology and National Comprehensive Cancer Network currently recommend that MRI screening be considered in addition to annual mammography for women with atypical hyperplasia.

• #70 Atypical hyperplasia of the breast | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/non-cancerous-conditions/atypical-hyperplasia

  Hyperplasia is an increase in the number of normal cells growing in a tissue. Atypical hyperplasia means that the cells that are increasing in a tissue are abnormal. […] Having atypical hyperplasia increases the risk for breast cancer. This risk is even higher in women who have a family history of breast cancer or who are diagnosed with atypical hyperplasia before they reach menopause. Breast cancer is more likely to start in the breast where atypical hyperplasia is found. The risk of developing breast cancer is greatest 10-15 years after atypical hyperplasia is diagnosed. The risk begins to go down after 15 years. […] Women with atypical hyperplasia should talk to their doctor about a personal plan of testing for breast cancer, including regular mammography. […] Atypical hyperplasia of the breast does not cause any symptoms. It is usually found during screening mammography. […] Women with atypical hyperplasia should talk to their healthcare team about the benefits and possible risks of taking SERMs to reduce their risk of breast cancer.

• #71 Atypical Hyperplasia – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/breast-cancer-explained/atypical-hyperplasia/

  If you are diagnosed with atypical hyperplasia ductal or lobular your doctor may suggest that you consider taking tamoxifen. […] Chemoprevention with tamoxifen or raloxifene is not a mandatory treatment. It is a choice. […] If you decide to have genetic testing and if you are found to carry one of the BRCA gene mutations that put women at higher risk for breast and ovarian cancer, your doctor may suggest that you consider a bilateral prophylactic mastectomy (removal of both breasts).

• #72 Breast Cancer Risk: Usual and Atypical Hyperplasia | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/hyperplasia-and-other-benign-breast-conditions/

  Atypical hyperplasia is less common than usual hyperplasia. […] Women with atypical hyperplasia have about 3 to 5 times the breast cancer risk of women without a proliferative breast condition. […] For women with atypical hyperplasia who also have a 20% or greater lifetime risk of invasive breast cancer, there are special breast cancer screening recommendations. […] The NCCN strongly recommends women with atypical hyperplasia take a risk-reducing drug (such as tamoxifen) to lower their risk of developing breast cancer. […] These drugs can lower the risk of breast cancer in women with atypical hyperplasia by about 86%.

• #73 Navigating breast health: a comprehensive approach to atypical ductal hyperplasia of the breast management and surveillance

  https://www.explorationpub.com/Journals/em/Article/1001205

  The vast majority of ADH is estrogen receptor positive and adjuvant endocrine therapy with selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene or aromatase inhibitors (AIs) such as anastrozole and exemestane, is offered to patients who are diagnosed with ADH of the breast. […] In summary, surgical excision is the standard of care for most patients with ADH. […] Due to the high lifetime risk of breast cancer, all patients diagnosed with ADH should be offered lifelong clinical surveillance with clinical breast examination every 6-12 months, annual diagnostic MMO with tomography, and enhanced surveillance with annual MRI.

• #74 Atypical hyperplasia of the breast – Hancock Health

  https://www.hancockhealth.org/mayo-health-library/atypical-hyperplasia-of-the-breast/

  Atypical hyperplasia of the breast increases the risk of breast cancer. So your healthcare team creates a breast cancer screening plan. You might have more-frequent screening or different screening tests than would someone with an average risk of breast cancer. […] Medicines that block the hormone estrogen in the body can lower the risk of breast cancer. Most breast cancers use estrogen and other hormones to help the cancer grow. Blocking estrogen helps stop cancer from forming. […] Atypical hyperplasia of the breast may be treated with surgery to remove the atypical cells. This might be recommended if mammogram images show something concerning. […] Not everyone with atypical hyperplasia of the breast needs surgery. Some healthcare teams may not recommend surgery if there is a low risk of finding cancer.

• #75 Atypical hyperplasia of the breast – Hancock Health

  https://www.hancockhealth.org/mayo-health-library/atypical-hyperplasia-of-the-breast/

  If you have a very high risk of breast cancer, your healthcare team might recommend surgery to lower your risk. […] To reduce your risk of breast cancer, your healthcare team may recommend that you avoid hormone therapy for menopause. […] If a mammogram reveals a suspicious area in your breast, your healthcare professional may refer you to a breast health specialist or a specialized breast center. If you have atypical hyperplasia of the breast, a breast health specialist can help you understand your breast cancer risk and create a plan to help you manage the risk.

• #76 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  Relative risk reductions in the atypical hyperplasia subgroup were even greater and ranged from 41% up to 79%. […] Despite the evidence that chemoprevention medications work, patients are reluctant to take them due to fear of side effects. […] The risk of venous thromboembolisms with these medications ranges from 5.9 to 14 per 1000 women.

• #77 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  Relative risk reductions in the atypical hyperplasia subgroup were even greater and ranged from 41% up to 79%. […] Despite the evidence that chemoprevention medications work, patients are reluctant to take them due to fear of side effects. […] The risk of venous thromboembolisms with these medications ranges from 5.9 to 14 per 1000 women.

• #78 Atypical Ductal Hyperplasia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK562244/

  There is no role at this time for radiation therapy in a patient diagnosed only with atypical ductal hyperplasia. […] Complications of atypical ductal hyperplasia result from both over and undertreating the diagnosis. There is a risk of missing a breast carcinoma with undertreatment of ADH and not proceeding with additional tissue sampling. […] Patients diagnosed with ADH should be followed closely by a clinician, given a higher risk of breast carcinoma in the future. […] Atypical ductal hyperplasia is a pathology finding, usually found incidentally on biopsy of the breast. The diagnosis by itself is not a precancerous or cancerous lesion. It is, however, a high-risk lesion, indicating the presence of ADH on pathology flags the patient as one who is fivefold more likely to develop breast carcinoma – in any area of the breasts – in the future.

• #79 Hyperplasia and atypical hyperplasia | Breast Cancer Now

  https://breastcancernow.org/about-breast-cancer/breast-lumps-and-benign-not-cancer-breast-conditions/hyperplasia-and-atypical-hyperplasia/

  If you have atypical hyperplasia, you may need follow-up such as yearly mammograms. […] If you have atypical hyperplasia, your risk of breast cancer is increased. Your treatment team will explain if and how you will be followed up. […] Go back to your GP if you notice any changes, no matter how soon they appear after your diagnosis of atypical hyperplasia.

• #80 Navigating breast health: a comprehensive approach to atypical ductal hyperplasia of the breast management and surveillance

  https://www.explorationpub.com/Journals/em/Article/1001205

  The vast majority of ADH is estrogen receptor positive and adjuvant endocrine therapy with selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene or aromatase inhibitors (AIs) such as anastrozole and exemestane, is offered to patients who are diagnosed with ADH of the breast. […] In summary, surgical excision is the standard of care for most patients with ADH. […] Due to the high lifetime risk of breast cancer, all patients diagnosed with ADH should be offered lifelong clinical surveillance with clinical breast examination every 6-12 months, annual diagnostic MMO with tomography, and enhanced surveillance with annual MRI.

• #81 Atypical hyperplasia of the breast | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/non-cancerous-conditions/atypical-hyperplasia

  Hyperplasia is an increase in the number of normal cells growing in a tissue. Atypical hyperplasia means that the cells that are increasing in a tissue are abnormal. […] Having atypical hyperplasia increases the risk for breast cancer. This risk is even higher in women who have a family history of breast cancer or who are diagnosed with atypical hyperplasia before they reach menopause. Breast cancer is more likely to start in the breast where atypical hyperplasia is found. The risk of developing breast cancer is greatest 10-15 years after atypical hyperplasia is diagnosed. The risk begins to go down after 15 years. […] Women with atypical hyperplasia should talk to their doctor about a personal plan of testing for breast cancer, including regular mammography. […] Atypical hyperplasia of the breast does not cause any symptoms. It is usually found during screening mammography. […] Women with atypical hyperplasia should talk to their healthcare team about the benefits and possible risks of taking SERMs to reduce their risk of breast cancer.

Zobacz więcej